Brought to you by 
AZ gets antibody technology rights from Regeneron; deal terminated
15 Mar 2012
Executive Summary
AstraZeneca has licensed from Regeneron (drug discovery for ophthalmic conditions, cancer, and inflammation) nonexclusive rights to the VelocImmune human monoclonal antibody discovery technology. AZ will develop therapeutic antibodies for undisclosed conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ gets antibody technology rights from Regeneron; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice